Kidney Failure, Chronic Clinical Trial
Official title:
A Phase Ib, Single- and Multiple-Dose, Open-Label Study of The Safety, Pharmacokinetics and Pharmacodynamics of Obinutuzumab in Adults With End-Stage Renal Disease and Hypersensitization Awaiting Renal Transplantation
This is a Phase Ib, open-label study of single and repeat doses of obinutuzumab administered
as intravenous (IV) infusion in adults with end stage renal disease (ESRD). Participants will
be enrolled into two cohorts receiving either one (Cohort 1) or two or more (Cohort 2)
obinutuzumab infusions. Both cohorts will receive standard pretreatments to reduce the risk
of infusion-related reactions (IRRs).
Desensitization Period: In Cohort 1, participants will receive single dose obinutuzumab IV
infusion on Day 1. Following review of Cohort 1 aggregated safety data up to 4 weeks post
dose for the last participant of Cohort 1, Cohort 2 will be allowed to proceed. In Cohort 2,
participants will receive obinutuzumab IV infusion on Days 1 and 15. Transplantation Period:
Participants who qualify for transplantation and receive a compatible kidney offer after
inclusion in Cohort 1 or Cohort 2 will receive two additional infusions (one at the time of
transplantation and second at Week 24 post-transplantation) of obinutuzumab. Assessment of
the safety and tolerability of the obinutuzumab regimen will be conducted at Week 24 of the
desensitization phase and at Week 28 post-transplantation. All participants will be monitored
for a minimum of 12 months following the last obinutuzumab infusion.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03246984 -
VALUE- Vascular Access Laminate eUropean Experience. A Post Market Surveillance Study to Assess the Safety and Effectiveness of VasQ
|
N/A | |
| Completed |
NCT02922361 -
Spending and Outcomes for Complex Medicare Advantage Patients
|
||
| Completed |
NCT02235571 -
iChoose Decision Kidney Aid for End-Stage Renal Disease Patients
|
N/A | |
| Completed |
NCT01933789 -
Improving Communication About Serious Illness
|
N/A | |
| Completed |
NCT01922843 -
A Phase 2 Study of an Oral Vitamin D Compound (DP001) in Secondary Hyperparathyroidism in Patients on Hemodialysis
|
Phase 2 | |
| Completed |
NCT01930396 -
Use of Tinzaparin for Anticoagulation in Hemodialysis
|
Phase 4 | |
| Not yet recruiting |
NCT01674660 -
Factors Associated With Interdialytic Blood Pressure Variability in Maintenance Hemodialysis Patients
|
N/A | |
| Completed |
NCT01209403 -
Insulin-like Growth Factor (IGF-I) in Hemodialysis Patients
|
Phase 4 | |
| Not yet recruiting |
NCT01157260 -
The Effects of AST-120 on Endothelial Dysfunction in Patients With Chronic Kidney Disease
|
Phase 4 | |
| Completed |
NCT00753116 -
Renal Denervation in End Stage Renal Disease Patients With Refractory Hypertension
|
Phase 1 | |
| Recruiting |
NCT00532688 -
N-Acetylcysteine in Heart Failure With Coexistent Chronic Renal Failure
|
Phase 2/Phase 3 | |
| Completed |
NCT00534144 -
Comparison Between Effects of Two Iron Preparations on Protein in the Urine
|
Phase 1 | |
| Completed |
NCT00528788 -
How Vitamin D Analogues Affect Endothelial Cells in Patients on Dialysis
|
Phase 4 | |
| Completed |
NCT00226902 -
Vascular Reactivity in Kidney Disease Patients
|
N/A | |
| Completed |
NCT00382044 -
Audit of the Effect of Changing From IV to SC Administration of ESA's in Haemodialysis Patients
|
N/A | |
| Recruiting |
NCT00235287 -
Pulse Wave Velocity, Pulse Wave Morphology and Blocking of the Reninangiotensin System in Patients With Chronic Kidney Disease
|
Phase 4 | |
| Completed |
NCT00224081 -
DRIVE Trial (Dialysis Patients' Response to Intravenous [IV] Iron With Elevated Ferritin)
|
Phase 4 | |
| Completed |
NCT00071214 -
Study to Evaluate the Effectiveness of StaphVAX in Adults on Hemodialysis
|
Phase 3 | |
| Completed |
NCT00049907 -
Cardiac and Renal Disease Study (CARDS)
|
N/A | |
| Completed |
NCT00006297 -
Risk Factors for CV Disease in a Dialysis Cohort
|
N/A |